초록 ▼

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

대표청구항 ▼

1. A method of inhibiting adverse effects of transplantation in a subject that has undergone, is undergoing, or will undergo a kidney allotransplant procedure comprising administering to the subject, or pretreating the kidney to be transplanted with, a composition comprising a monoclonal MASP-2 inhi

1. A method of inhibiting adverse effects of transplantation in a subject that has undergone, is undergoing, or will undergo a kidney allotransplant procedure comprising administering to the subject, or pretreating the kidney to be transplanted with, a composition comprising a monoclonal MASP-2 inhibitory antibody, or antigen-binding fragment thereof, that specifically binds to a portion of SEQ ID NO:6 and selectively inhibits MASP-2 dependent complement activation without substantially inhibiting C1q-dependent complement activation. 2. The method of claim 1, wherein the MASP-2 inhibitory monoclonal antibody, or antigen binding fragment thereof, specifically binds to a polypeptide comprising SEQ ID NO:6. 3. The method of claim 1, wherein the MASP-2 inhibitory monoclonal antibody, or antigen-binding fragment thereof, specifically binds to a polypeptide comprising SEQ ID NO: 6 with an affinity of at least 10 times greater than it binds to a different antigen in the complement system. 4. The method of claim 1, wherein the MASP-2 monoclonal antibody or antigen-binding fragment thereof is recombinant. 5. The method of claim 1, wherein the MASP-2 monoclonal antibody or antigen-binding fragment thereof has reduced effector function. 6. The method of claim 1, wherein the MASP-2 monoclonal antibody or antigen-binding fragment thereof is chimeric, humanized or human. 7. The method of claim 1, wherein the composition is administered to the subject by at least one of intra-arterial, intravenous, intramuscular, or subcutaneous administration. 8. The method of claim 1, wherein the method comprises pretreating the kidney to be transplanted with the composition comprising the monoclonal MASP-2 inhibitory antibody, or antigen-binding fragment thereof, that specifically binds to a portion of SEQ ID NO:6 and selectively inhibits MASP-2 dependent complement activation without substantially inhibiting C1q-dependent complement activation. 9. The method of claim 7, wherein the method comprises administering the composition to the subject prior to the transplant procedure. 10. The method of claim 7, wherein the method comprises administering the composition to the subject during the transplant procedure. 11. The method of claim 7, wherein the method comprises administering the composition to the subject during the acute period following the transplant procedure. 12. The method of claim 7, wherein the method comprises administering the composition to the subject as a long term post-transplantation therapy.